Back to Stakeholders
Categories

2 domains / 4 areas / 2 specializations

Care Delivery & Psychedelic Facilitation
Care Delivery & Psychedelic Facilitation
Clinical Care Delivery OrganizationsHealth Systems & Hospitals
Research, Drug Development & Manufacturing
Academic & Non-Profit ResearchUniversities and Colleges without Dedicated Psychedelic Research Groups
Research, Drug Development & Manufacturing

Psychiatric University Hospital, Zurich

Data updated

Switzerland
5 Trials1 Paper

The Psychiatric University Hospital Zurich (PUK) is affiliated with the University of Zurich and home to Franz Vollenweider's pioneering psychedelic neuroscience group, active since the 1990s; research includes PET imaging with psilocybin, S- and R-ketamine, MDMA, and DMT+harmine formulations, including a completed 2023 RCT of psilocybin (0.215 mg/kg) vs. placebo for major depressive disorder.

Academic Research

1 papers

Published Papers

1

Trial Involvement

5

Distinct Focus Topics

0

Latest Publication

Mar 18, 2026

Clinical Care Delivery Snapshot

Health Systems & Hospitals

Provider Model

Health System / Hospital Program

Organization Status

Unknown

Psychedelic Services

Unknown

Service Coverage

Global

Service Profile

Care Settings

Hospital Outpatient

Payer Models

Unknown

Non-Psychedelic Service Mix

Unknown

Visit Provider

Care Delivery Notes

Backfilled profile for existing L2 clinical care delivery stakeholder.

Sources

Official website

https://www.pukzh.ch

Quick Facts

Type
Other
HQ
Switzerland
Website
Visit

Sponsored Trials

4
CompletedI

Mindfulness and Psychedelics

Start Date
CompletedI

Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects

Start Date
Compounds
DMT, Placebo
CompletedI

A Multimodal Neuroimaging Study of Brain Activation Patterns Under Ketamine

Start Date
Compounds
Ketamine, Placebo
CompletedNA

The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers

Start Date
Compounds
Placebo, LSD

Collaborated Trials

1
CompletedI

Molecular Imaging Study of Harmine/DMT: a Basic Research Approach (HaD-PET)

Start Date
Compounds
Ayahuasca, Placebo

Research Papers

1
Open AccessindividualPrimary

Mixed-methods analysis on psychedelic-augmented meditation experiences from a randomized controlled mindfulness retreat

This secondary analysis of a randomised controlled trial of DMT/harmine in experienced meditators found that meditation under DMT-harmine differed from placebo in its thematic and experiential profile while still sharing some semantic features. Using NLP-based analysis of phenomenological interviews, the study also suggested overlap between meditative and psychedelic states and highlighted the strong influence of context and spiritual framing on subjective experience.

Published
Journal
Scientific Reports
Authors
Schlomberg, J. T. T., Meling, D., Grylka, R., Vasella, E. A., Augustinovic, D., Scheidegger, M.